What is the primary purpose of raloxifene in postmenopausal women?

Raloxifene is primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women. It is a selective estrogen receptor modulator (SERM) that mimics estrogen in certain tissues, particularly in bone. By binding to estrogen receptors in bone tissue, raloxifene helps to maintain bone density and reduce the risk of osteoporosis-related fractures, which is a significant concern for postmenopausal women due to decreased estrogen levels leading to bone loss.

In contrast, other medications or interventions would typically address the other options mentioned, such as controlling blood pressure or reducing cholesterol levels. Mood enhancement can involve different types of medications or therapies altogether. Thus, the primary function of raloxifene relates specifically to bone health and fracture prevention in the context of osteoporosis following menopause.